{"id":"https://openalex.org/W2156159243","doi":"https://doi.org/10.1002/cpdd.59","title":"Population pharmacokinetics and safety of AZD1446, a neuronal nicotinic receptor agonist, administered in healthy volunteers","display_name":"Population pharmacokinetics and safety of AZD1446, a neuronal nicotinic receptor agonist, administered in healthy volunteers","publication_year":2013,"publication_date":"2013-09-09","ids":{"openalex":"https://openalex.org/W2156159243","doi":"https://doi.org/10.1002/cpdd.59","mag":"2156159243","pmid":"https://pubmed.ncbi.nlm.nih.gov/27128232"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.59","doi":"https://doi.org/10.1002/cpdd.59","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.59","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5114247637","display_name":"Emma Bostr\u00f6m","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Emma Bostr\u00f6m","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021001789","display_name":"Kristina Claeson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Kristina Claeson Bohnstedt","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111972530","display_name":"Karl\u2010Gustav Jostell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Karl\u2010Gustav Jostell","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004396674","display_name":"Sofie Alverlind","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sofie Alverlind","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041232510","display_name":"Gunilla Huledal","orcid":"https://orcid.org/0000-0001-8114-1486","observed_orcids":["https://orcid.org/0000-0001-8114-1486"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Gunilla Huledal","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Bj\u00f6rn Paulsson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Paulsson","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110023837","display_name":"Hans\u2010G\u00f6ran H\u00e5rdemark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Hans\u2010G\u00f6ran H\u00e5rdemark","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034716213","display_name":"John \u00d6hd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"John \u00d6hd","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077349740","display_name":"Sara Lindholm","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sara Lindholm","raw_affiliation_strings":["AstraZeneca R&D S\u00f6dert\u00e4lje Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D S\u00f6dert\u00e4lje Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5114247637"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"3","issue":"1","first_page":"63","last_page":"71"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11818","display_name":"Nicotinic Acetylcholine Receptors Study","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11818","display_name":"Nicotinic Acetylcholine Receptors Study","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.125,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.120899997651577,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha4beta2-nicotinic-receptor","display_name":"alpha4beta2 nicotinic receptor","score":0.8579999804496765},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.9679999947547913},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.7940000295639038},{"id":"https://openalex.org/keywords/cognitive-disorders","display_name":"cognitive disorders","score":0.671999990940094},{"id":"https://openalex.org/keywords/inter-individual-variability","display_name":"interindividual variability","score":0.6859999895095825},{"id":"https://openalex.org/keywords/interoccasion-variability","display_name":"interoccasion variability","score":0.9129999876022339},{"id":"https://openalex.org/keywords/age-effects","display_name":"age effects","score":0.6240000128746033},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.8209999799728394},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5199999809265137},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5659999847412109}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9005587100982666},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8101832866668701},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6334137916564941},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.6188551187515259},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5588363409042358},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.547038733959198},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.519154965877533},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.4943358898162842},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4568643271923065},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4205136001110077},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2231992781162262},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1002/cpdd.59","doi":"https://doi.org/10.1002/cpdd.59","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.59","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:27128232","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27128232","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1486207314","https://openalex.org/W1607171655","https://openalex.org/W1895538680","https://openalex.org/W1987219819","https://openalex.org/W2004549794","https://openalex.org/W2042553471","https://openalex.org/W2048740041","https://openalex.org/W2052011640","https://openalex.org/W2055471148","https://openalex.org/W2085316111","https://openalex.org/W2109356111","https://openalex.org/W2130009335","https://openalex.org/W2134043280","https://openalex.org/W2137395053","https://openalex.org/W2148083007","https://openalex.org/W4234060991","https://openalex.org/W4319292982"],"related_works":["https://openalex.org/W2031773894","https://openalex.org/W2002997534","https://openalex.org/W1963597328","https://openalex.org/W2020831647","https://openalex.org/W2806100469","https://openalex.org/W3062840776","https://openalex.org/W1486207314","https://openalex.org/W1986712695","https://openalex.org/W1980742278","https://openalex.org/W2078776481"],"abstract_inverted_index":{"AZD1446":[0,44,88,114,173],"is":[1],"a":[2,47,145],"highly":[3],"selective":[4],"agonist":[5],"of":[6,31,43,52,75,87,131,141,159],"central":[7],"\u03b14\u03b22":[8],"and":[9,25,57,66,80,92,95,102,133,176,182],"\u03b12\u03b22":[10],"neuronal":[11],"nicotinic":[12],"receptors.":[13],"The":[14,61,108],"compound":[15],"has":[16,27],"been":[17],"shown":[18],"to":[19,162],"improve":[20],"cognition":[21],"in":[22,55,118,144,170],"preclinical":[23],"studies":[24,54],"thus":[26],"potential":[28],"for":[29],"treatment":[30],"cognitive":[32],"disorders,":[33],"including":[34],"Alzheimer's":[35],"disease":[36],"(AD).":[37],"This":[38],"report":[39],"presents":[40],"the":[41,64,73,83,96,185],"pharmacokinetics":[42],"based":[45],"on":[46,82],"pooled":[48],"population":[49],"pharmacokinetic":[50],"analysis":[51],"five":[53],"Caucasian":[56,122],"Japanese":[58,124],"healthy":[59],"volunteers.":[60],"model":[62],"described":[63],"inter-individual":[65],"inter-occasion":[67],"variability":[68,117],"as":[69,71,78,137,139,184],"well":[70,138,177],"identified":[72],"impact":[74],"covariates":[76],"such":[77],"age":[79],"ethnicity":[81],"parameters.":[84],"Single":[85],"doses":[86],"ranged":[89,99],"between":[90,100],"0.5":[91],"350":[93],"mg":[94,104],"multiple-dose":[97],"regimens":[98],"10":[101],"100":[103],"four":[105],"times":[106],"daily.":[107],"maximum":[109],"duration":[110],"was":[111,168,174],"4":[112],"weeks.":[113],"exhibited":[115],"modest":[116],"CL/F.":[119],"Compared":[120,148],"with":[121,149,179],"subjects,":[123,151],"subjects":[125,153],"had":[126,154],"approximately":[127,155],"25%":[128,156],"higher":[129,134],"rate":[130,158],"absorption":[132],"renal":[135,166],"clearance":[136,167],"volume":[140],"distribution,":[142],"resulting":[143],"similar":[146],"half-life.":[147],"elderly":[150,171],"young":[152],"lower":[157,163,169],"absorption.":[160],"Due":[161],"creatinine":[164],"clearance,":[165],"subjects.":[172],"safe":[175],"tolerated,":[178],"nausea,":[180],"headache":[181],"dizziness":[183],"most":[186],"frequently":[187],"reported":[188],"adverse":[189],"events.":[190]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}